Hainan hospital introduces an antibody–drug conjugate regimen for relapsed myeloma
The Second Affiliated Hospital of Hainan Medical University describes a BVd programme, outpatient infusion, adverse-reaction monitoring and long-term follow-up for myeloma patients.
Published by CareAtlas · Editorial policy
The hematology department at the Second Affiliated Hospital of Hainan Medical University announced the introduction of belantamab mafodotin, a BCMA-directed antibody–drug conjugate, for relapsed or refractory multiple myeloma. Its July 31, 2026 service update describes the treatment programme and the clinical arrangements supporting patients through assessment, infusion and follow-up.
A new combination in the myeloma service
The hospital describes a BVd regimen combining belantamab mafodotin with bortezomib and dexamethasone. Its dedicated myeloma team manages plasma-cell disorders and has experience with targeted treatment, immunotherapy, autologous stem-cell transplantation and antibody–drug conjugates.
The department identifies outpatient infusion as an option within the new programme, reducing the need for prolonged inpatient stays. Treatment planning is linked to specialist assessment. The hospital describes genetic testing and risk-stratified treatment among the steps in its myeloma care pathway.
A Sanya patient chooses care on the island
The account features Mr Chen, a 70-year-old resident of Sanya whose myeloma relapsed after three previous lines of standard treatment. He had bone pain and impaired kidney function. After learning that the hospital had introduced the antibody–drug conjugate, he chose to remain in Hainan for treatment.
His family described the burden of travelling outside the island for difficult blood disorders and welcomed being able to pursue care locally.
Infusion monitoring and continuing care
The department has established standardized infusion procedures and monitoring for adverse reactions. Supporting facilities include laminar-flow rooms and laboratory testing equipment.
It also maintains long-term follow-up records for myeloma patients, linking genetic assessment and treatment selection with adverse-reaction management and rehabilitation support. The hematology service treats referred complex cases from elsewhere in China and has experience receiving foreign patients. Its stated continuing work includes refining multidisciplinary assessment for plasma-cell disorders and the care processes for innovative medicines.